Psychedelic-assisted therapy: all studies (page 87)

Psychoactive plant derivatives (ayahuasca, ibogaine, kratom) and their application in opioid withdrawal and use disorder - a narrative review.

Journal of Addictive Diseases 2024 Alexandra Arenson, Cynthia I Campbell, Ilan Remler 8 citations

The opioid epidemic and limited access to treatment for opioid withdrawal (OW) and opioid use disorder (OUD) has led individuals to seek alternative treatments. This narrative review aims to educate clinicians on the mechanisms of action, toxicity, and applications of psychoactive plant-based substances patients may be using to self-treat OUD and OW. We specifically discuss ayahuasca, ibogaine,...

DOI: 10.1080/10550887.2023.2195777 Full text Ayahuasca Ibogaine Opioid use disorder Psychedelic therapy +6

Ensuring psychedelic treatments and research do not leave anyone behind.

Neuropsychopharmacology 2024 Melissa A Simon 6 citations

Psychedelics are a promising approach to caring for persons living with severe mental illness. However, as with all clinical treatments and research in the US, health equity concerns must be considered and addressed. Ensuring health equity and health justice in psychedelic care delivery and research will require strategies to not only reduce disparities and preempt future disparities among...

DOI: 10.1038/s41386-023-01710-4 Full text Psychedelic therapy Mental health equity Healthcare access Marginalized communities +1

IUPHAR-review: The integration of classic psychedelics into current substance use disorder treatment models.

Pharmacological Research 2024 David B. Yaden, Andrea P Berghella, Peter S. Hendricks et al. 12 citations

Substance use disorders (SUDs) have an enormous impact on public health. With classic psychedelic-assisted therapies showing initial promise in treating multiple SUDs, it is possible that these treatments will become legally available options for patients with SUDs in the future. This article highlights how classic psychedelic-assisted therapies might be integrated into current clinical...

DOI: 10.1016/j.phrs.2023.106998 Full text Psilocybin Substance use disorder Psychedelic therapy Medication assisted treatment +5

The Promise of Therapeutic Psilocybin: An Evaluation of the 134 Clinical Trials, 54 Potential Indications, and 0 Marketing Approvals on ClinicalTrials.gov.

Drug Design, Development and Therapy 2024 Sarah A Norring, Michael G Spigarelli 22 citations

Psilocybin, a tryptamine psychedelic, has been touted in the media both historically and recently as a potential game-changing mental health therapeutic. ClinicalTrials.gov has over one hundred and thirty psilocybin clinical trials listed covering the last twenty years. The single most important aspect of any therapeutic is to gain approval for marketing and thus enter the real-world phase of...

DOI: 10.2147/dddt.s443177 Full text Psilocin Psychedelic therapy FDA Approval Drug development +3

Attitudes of European psychiatrists on psychedelics: a qualitative study.

Frontiers in Psychiatry 2024 Marija Franka Žuljević, Nando Breški, Mariano Kaliterna et al. 6 citations

It is important to understand how mental health practitioners view recent findings on psychedelic-assisted psychotherapy (PAP) as there is potential this treatment may be incorporated into clinical practice. The aim of our study was to explore how psychiatrists who are not involved in psychedelic research and who are located in the European region perceive psychedelics and PAP. We conducted...

DOI: 10.3389/fpsyt.2024.1411234 Full text MDMA Psilocybin Psychedelic therapy Psychedelics +5

Theorizing that Psychedelic Assisted Therapy May Play a Role in the Treatment of Trauma-Induced Personality Disorders.

Journal of addiction psychiatry 2024 Gianni Martire, Daniel Sipple, David Baron et al. 341 citations

Borderline personality disorder (BPD) and post-traumatic stress disorder (PTSD) share overlapping neurobiological mechanisms particularly reward deficiency and stress-like anti-reward processes. And so, BPD may be reclassified as a "traumatic personality stress disorder" (TPSD) with ensuing common therapeutic strategies that may stabilize dopaminergic reward function such as...

DOI: 10.1016/j.psc.2018.07.008 Full text Post-traumatic stress disorder Psilocybin Psychedelic-assisted psychotherapy Personality disorders bpd +5

Ayahuasca-assisted meaning reconstruction therapy for grief: a non-randomized clinical trial protocol.

Frontiers in Psychiatry 2024 Pablo Sabucedo, Óscar Andión, Robert A Neimeyer et al. 4 citations

Psychotherapy for Prolonged Grief Disorder (PGD), a condition characterized by an intense and persistent grief response, has received increased attention over the past decades. Evidence-based approaches to prevent PGD are currently scarce, and not always effective. This paper introduces a protocol for a clinical trial exploring the effectiveness of a Meaning Reconstruction psychotherapy...

DOI: 10.3389/fpsyt.2024.1484736 Full text Ayahuasca Psychedelic-assisted therapy Bereavement Meaning reconstruction +9

MDMA-assisted therapy for borderline personality disorder

Journal of Psychedelic Studies December 14, 2023 Ann M. Inouye, Aaron Wolfgang, Lianne T. Philhower 1 citation

AbstractAssociated with high-risk behavior, borderline personality disorder (BPD) remains one of the field's most misunderstood, misdiagnosed, and stigmatized conditions. Individuals with BPD are frequently labeled as treatment-resistant patients. Furthermore, 25–58% of BPD individuals have a comorbid diagnosis of post-traumatic stress disorder (PTSD), and BPD may be conceptualized as a...

DOI: 10.1556/2054.2023.00196 Psychedelic therapy Post-traumatic stress disorder Ecstasy therapy Personality disorder +4

Exploring the Unique Therapeutic Potential of Psychedelics to Reduce Chronic Shame Among Sexual and Gender Minority Adults.

Psychedelic Medicine December 13, 2023 Nicholas A. Carlisle, Haley Maria Dourron, Sarah Maccarthy et al. 12 citations

Recent trials of psychedelic-assisted therapy have suggested potential efficacy for the treatment of many health conditions that disproportionately impact sexual and gender minority (SGM) people, including major depressive disorder and alcohol and tobacco use disorders. Despite these promising findings, the potential benefits of psychedelics for SGM people have been largely ignored. First, we...

DOI: 10.1089/psymed.2022.0018 Full text Psychedelic-assisted therapy Psychedelic therapy Pat Entheogenic therapy +16

Preventing the Gaps in Psychedelic Research from Becoming Practice Pitfalls: A Translational Research Agenda.

Psychedelic Medicine December 13, 2023 Andrew Penn, Rachel Yehuda 7 citations

The reemergence of psychedelic medicines as clinical treatments has generated considerable interest in both professional and popular arenas. Although evidence is promising for psychedelic-assisted therapy (PAT), there is much that is not yet known and needs to be researched so as to understand how to safely and effectively utilize PAT in clinical populations and to most effectively deploy PAT...

DOI: 10.1089/psymed.2023.0017 Full text Psychedelic therapy Mental health treatment Clinical standards Medical safety protocols +1